YouTube on MSN

Better than statins? The truth about the new cholesterol drug

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
The American Journal of Managed Care

PCSK9 Inhibitors and CV Risk

The role of PCSK9 inhibitors as treatment for dyslipidemia now that statin therapies are available. Deepak L. Bhatt, MD, MPH: Speaking of PCSK9 inhibitors, let’s turn back to Dr Budoff. I was going to ...
MM&M

Can the third PCSK9 drug succeed where the first two failed?

In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...
TCTMD

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Although some of the barriers that have kept cholesterol-lowering PCSK9 inhibitors out of reach for many patients in the United States have eased a bit in recent years, a new analysis suggests that ...
EurekAlert!

Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing

The upregulation of PCSK9 expression in endothelial cells of diabetic patients induces ubiquitination of VEGFR2 and inhibits the VEGFR2/ AKT/eNOS -ERK signaling pathway by promoting the interaction of ...
Healio

Access to PCSK9 inhibitors challenging, but resources may help

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Prescriptions for PCSK9 inhibitors are often denied by payers, but having access to the ...
MedPage Today

Third-Generation PCSK9 Inhibitor Cuts Cholesterol With Single, Small, Monthly Shot

ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by ...
Healio

Breaking down barriers: How to optimize access, use of PCSK9 inhibitors

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
MedPage Today

Novel PCSK9 Inhibitor Recaticimab Lowers Lipids With Less Frequent Shots

PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...
Fierce Pharma

FDA untitled letter skewers Esperion's claims about cholesterol med Nexlizet in TV ad

The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...
Kaleido Scope

PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort

Elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels have been associated with adverse outcomes in patients hospitalized for sepsis. PCSK9 loss-of-function (LOF) variants area ...